Baseline Characteristics of the VANISH Cohort

• Published in: Circulation. Heart failure Vol. 12; no. 12; p. e006231
• Main Authors: Axelsson Raja, Anna, Shi, Ling, Day, Sharlene M, Russell, Mark, Zahka, Kenneth, Lever, Harry, Colan, Steven D, Margossian, Renee, Hall, E Kevin, Becker, Jason, Jefferies, John Lynn, Patel, Amit R, Choudhury, Lubna, Murphy, Anne M, Canter, Charles, Bach, Richard, Taylor, Matthew, Mestroni, Luisa, Wheeler, Matthew T, Benson, Lee, Owens, Anjali T, Rossano, Joseph, Lin, Kimberly Y, Pahl, Elfriede, Pereira, Alexandre C, Bundgaard, Henning, Lewis, Gregory D, Vargas, Jose D, Cirino, Allison L, McMurray, John J V, MacRae, Calum A, Solomon, Scott D, Orav, E John, Braunwald, Eugene, Ho, Carolyn Y
• Format: Journal Article
• Language: English
• Published: United States 01.12.2019
• Subjects: cardiomyopathy, hypertrophic; angiotension receptor blocker; randomized controlled trial

The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease progression. We describe the baseline charac...